Skip to main content

Aptahem AB (publ) (APTA.ST)

Euronext Healthcare BiotechnologyView data quality →
41.3Fair

ValueMarkers Composite Index

Top 8%#41,345 of 44,714
Overvalued

327% above intrinsic value ($0)

UndervaluedFair ValueOvervalued
Piotroski
2/9
Weak
Beneish
-
Altman
3.28
Safe
DCF Value
$0
Overvalued
ROIC
-9.6%
Low
P/E
-
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

Aptahem AB (publ) (APTA.ST) — VMCI valuation read

Across 120 indicators, Aptahem AB (publ) (APTA.ST) lands at VMCI 41/100. The Healthcare sector median is 50, so the 9-point below-median read is the active comparison. Pillar weighting on the score: Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%.

No material Form 4 disclosures landed on APTA.ST in the past 30 days. Quiet insider tape removes one signal source; the active reads stay with the trailing-twelve-month financials and the next 10-Q.

**Investor frame.** On Value, APTA.ST trades at 21.0x earnings, 17% above the Healthcare median of 18.0x; the EV/EBITDA delta of -2.0x reinforces that single line. On Quality, ROIC of 13.0% sits 3.0pp above the Healthcare median (10.0%). On Risk, net debt to EBITDA of 2.6x is the rate-sensitivity line to watch for APTA.ST on the trailing balance sheet.

APTA.ST rose 3.8% over the trailing 7 days, with a -6.0% read on a 30-day basis.

Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.

Browse More

Key metrics explained

Definitions, formulas, and how ValueMarkers calculates each indicator used in APTA.ST’s VM Score.

Explore More

Compare Competitors

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.